



CLINICAL INVESTIGATIVE STUDY

The role of MRI in the prognosis of Wernicke's encephalopathy

Tomoaki Kitaguchi¹ | Yoshiaki Ota^{2,†} | Eric Liao² | Toshio Moritani² |
Gaurang Shah² | Kei Yamada¹ | Ashok Srinivasan²¹Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan²Division of Neuroradiology, Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA**Correspondence**Yoshiaki Ota, Division of Neuroradiology, Department of Radiology, University of Michigan, 1500 E Medical Center Dr, UH B2, Ann Arbor, MI 48109, USA.
Email: yoshiako@med.umich.edu; ooyayoshiaki@gmail.com[†]Co-first author.**Funding information**

None

Abstract**Background and Purpose:** Wernicke's encephalopathy (WE) is a severe acute disorder related to thiamine deficiency. This study was aimed at revealing the relationship between clinical and imaging findings and WE recovery.**Methods:** We retrospectively reviewed 34 cases of WE diagnosed between 2003 and 2020 (median age: 57 years, 14 females) at two academic institutions. WE cases were divided into two groups with symptomatic recovery within 4 weeks (group 1) or later (group 2). The lesion sites were divided into typical and atypical sites (total sites defined as when either typical or atypical sites were involved). Clinical and MRI features were compared between them as appropriate.**Results:** WE patients were divided into group 1 (19 cases, median age: 57 years, 10 females) and group 2 (15 cases, median age: 57 years, four females). Regarding clinical features, only cerebellar ataxia was more often observed in group 1 than in group 2. Regarding MRI features, signal abnormality on T2-weighted image (WI)/fluid-attenuated inversion recovery (FLAIR) was more often observed in atypical sites between groups 1 and 2 (1/19 vs. 7/15; $p = .01$). There were significant differences between groups 1 and 2 regarding the presence of both vasogenic edema and cytotoxic edema in total sites (4/11 vs. 11/15, $p = .005$; 1/19 vs. 6/15, $p = .03$), with a significant difference in the presence of vasogenic edema in typical sites (4/19 vs. 10/15, $p = .01$).**Conclusion:** The early recovered group showed a lower incidence of T2WI/FLAIR abnormality in atypical sites and diffusion signal abnormality in total or typical sites with a lower incidence of cerebellar ataxia.**KEYWORDS**

DWI, prognosis, Wernicke's encephalopathy

INTRODUCTION

Wernicke's encephalopathy (WE) is an acute neurologic disorder caused by thiamine deficiency with prevalence of 0.4%-2.8% in the general population.¹⁻⁷ If not appropriately treated, WE can lead to Korsakoff syndrome or death. The classical triad of clinical symptoms

includes mental status change, ataxia, and oculomotor abnormalities, and the most common cause of thiamine deficiency is alcoholism, accounting for about 50% of WE cases.⁶ There have been other reported causes of WE such as hyperemesis gravidarum, fasting, hemodialysis, uremia, hyperalimentation, and gastric surgery. Moreover, the classic triad of symptoms are found in only 16%-33% of WE

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Journal of Neuroimaging* published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.



patients on initial examination, and about 19% of patients have none of the classic triad, making the diagnosis of WE challenging.^{8,9}

Magnetic resonance imaging (MRI) is currently considered the standard imaging modality to confirm a diagnosis of WE. MRI has a sensitivity of only 53% but has a high specificity of 93%.^{10,11} Typical imaging findings of WE can be seen as symmetrical signal abnormalities in the periventricular regions of the thalamus, hypothalamus, mamillary bodies, periaqueductal region, and floor of the fourth ventricle. Additionally, MRI findings can be seen in the paravermian region of the cerebellum, dorsal medulla, pons, cranial nerve nucleus (CNN), red nucleus, dentate nucleus, putamen, caudate nucleus, fornix, splenium of the corpus callosum, and pre- and postcentral gyri.^{12,13,14} The above-mentioned lesions can show hyperintensity on T2-weighted image (WI) and fluid-attenuated inversion recovery (FLAIR) with or without contrast enhancement or abnormal signal on diffusion-weighted imaging (DWI).

The prognosis of patients with WE can vary, depending on the time of onset of thiamine supplementation, the degree of thiamine deficiency, and the underlying condition of the patient.⁸ Typically, recovery from the ophthalmoplegia is complete after a few hours, except for a residual fine, horizontal nystagmus in 60% of patients. Recovery from ataxia often occurs after a period of a few days, although in some cases is incomplete.^{15,16} The changes in mental status tends to improve after 2-3 weeks of therapy.^{15,16} Prior studies have shown that poor prognosis is related to the underlying etiology of WE and location of the lesions,¹⁷ but the relationship between the prognosis and clinical and MRI features has not been fully revealed. Clinically, it is of importance for both clinicians and radiologists to recognize the prognosis of patients with WE for clinical management. Persistent symptoms, permanent Korsakoff syndrome, or death occur even after appropriate treatment, and these conditions can be defined as poor prognosis.⁷

Therefore, the aim of this study was to investigate clinical and MRI features relating to the clinical outcome of WE.

METHODS

Study population

This international multicenter retrospective study was approved by each center's institutional review board, and informed consent was waived.

We retrospectively reviewed 34 cases of WE (median age, 57 years; age range, 19-86 years; 14 females) with available MRI at WE diagnosis from April 2003 to October 2020 in two academic centers. All consecutive cases of WE during the study period were reviewed (29 and 5 patients collected from each institution, respectively). The diagnosis of WE was determined with consensus by radiology and neurology departments based on imaging and clinical features. Clinical follow-up was performed and assessed by the neurology department at each institution. Based on this assessment, the cohort

was divided into two groups: patients whose neurologic symptoms resolved or returned back to baseline within 4 weeks after the diagnosis (group 1) and patients whose neurologic symptoms persisted 4 weeks after the diagnosis or who developed Korsakoff syndrome or died during follow-up (group 2). All patients were treated with intravenous infusion of 500-1000 mg of thiamine after the diagnosis of WE.

Patient demographics

Patient demographics were obtained from the electronic medical records and included the following information: sex, age, symptoms at the diagnosis, cause of thiamine deficiency (alcohol, a history of gastric surgery, malnutrition), history of malignancy and chemotherapy, and time to recovery after thiamine administration.

MRI acquisition

MRI examinations in all cases were performed during the acute symptomatic phase of WE with multiple scanners including the following: 1T scanner ($n = 2$ Panorama HFO, Philips; $n = 1$ GENESIS SIGNA, GE); 1.5T scanner ($n = 10$ Achieva, Philips Healthcare; $n = 4$ Intera, Philips Healthcare; $n = 1$ Optima, GE; $n = 4$ GENESIS SIGNA, GE; $n = 4$ SIGNA EXCITE, GE); and 3T scanner ($n = 4$ Ingenia, Philips Healthcare; $n = 1$ Achieva, Philips Healthcare; $n = 1$ Magnetom Vida, Siemens; $n = 1$ Skyra, Siemens). Reviewed sequences included axial T2WI, axial FLAIR, axial T1WI, axial postcontrast T1WI, and DWI. MRI was performed with contrast for 25 patients. The initial MRI at the time of diagnosis was evaluated.

MRI features

Two board-certified radiologists with 8 and 9 years of experience interpreted all MRI sequences with consensus. They were aware of the diagnosis, but were blinded to the clinical information. Both radiologists evaluated T2WI, FLAIR, DWI, and postcontrast T1WI (if available) in the following sites: typical sites (thalamus, periaqueductal area, periventricular region of the third ventricle, mamillary bodies, hypothalamus, and tectal plate) and atypical sites (cerebellum, medulla, corpus callosum, pre- and postcentral gyri, basal ganglia, olive nuclei, and cranial nerve nuclei [CNN] [VI, VII, VIII, XII]).

The presence of hyperintensity on T2WI/FLAIR, vasogenic edema (high signal on DWI and ADC) or cytotoxic edema (high signal on DWI and low signal on ADC), and enhancement was recorded as binary variables, and each binary variable was compared between the two groups in three patterns: in total sites (abnormal signal involving either typical or atypical sites), in the typical sites, and in the atypical sites. Each site was considered positive when a signal abnormality was identified in at least one anatomical region.

**TABLE 1** Patient demographics.

	Early recovered	Delayed recovered	p value
No. of patients	19	15	NA
Sex (female/all)	53%	27%	.17
Age (year)	57 (23-79)	55 (19-86)	.26
Alcohol (yes/all)	68%	40%	.17
Malnutrition (yes/all)	11%	40%	.10
Gastric surgery (yes/all)	21%	13%	.67
History of malignancy (yes/all)	5%	13%	.57
History of chemotherapy (yes/all)	0%	0%	NA
Altered mental status (yes/all)	63%	67%	1
Abnormal of eye movement (yes/all)	47%	60%	.51
Cerebellar ataxia (yes/all)	68%	20%	.007
Presence of symptoms other than classic triad (yes/all)	79%	80%	1
Time to recovery after thiamine administration (day)	7 (1-21)	40 (28-96) ^a	NA

Note: Values of age and time to recovery after thiamine administration are described as median (interquartile range).

Abbreviation: NA, not applicable.

^aFour patients passed away, and the time to recovery for these cases represents days from starting thiamine administration to death.

Statistical analysis

Continuous variables, such as age, were compared using the Mann-Whitney *U* test. The categorical values of clinical features (sex, neurological symptoms, and cause of thiamine deficiency) were compared between the two groups using the Fischer exact test. Regarding MRI features, binary variables of presence of hyperintensity on T2WI/FLAIR, presence of vasogenic edema (high signal on DWI and ADC) or cytotoxic edema (high signal on DWI and low signal on ADC), and presence of enhancement were compared between the two groups using the Fischer exact test.

All statistical calculations were conducted using R software (version 4.1.1; R Core Team, Vienna, Austria). Variables with *p*-values of <.05 were considered statistically significant.

RESULT

Patient demographics

Table 1 summarizes overall patients' clinical information, including sex and age, cause of thiamine deficiency, presence of clinical symptoms, and time to recovery after thiamine administration.

Group 1, which consisted of patients who recovered within 4 weeks (*n* = 19; median age, 57 years; 10 female), showed history of alcohol

abuse (13 cases), malnutrition (two cases), gastric surgery (four cases), and malignancy (one case: gastric cancer).

Group 2, patients with delayed recovery or irreversible symptoms (*n* = 15; median age, 55 years; four females), had a history of alcohol abuse (six cases), malnutrition (six cases), gastric surgery (two cases), and malignancy (two cases: gastric cancer, breast cancer). There was no history of chemotherapy. Four patients died from complications of WE such as Korsakoff syndrome and heart failure.

There was no significant difference in sex (female/male, 10/9 vs. 4/11, *p* = .17), age (median, 57 vs. 55, *p* = .26), cause of thiamine deficiency (presence of alcohol abuse, 13/19 vs. 6/15, *p* = .17; presence of malnutrition, 2/19 vs. 6/15, *p* = .10; or presence of gastric surgery, 4/19 vs. 2/15, *p* = .67).

Neurological features

The most frequent neurologic symptom at the time of diagnosis of WE was altered mental status (22/34 total; 12/19 group 1 vs. 10/15 group 2, *p* = 1). Eighteen patients showed abnormality of eye movement (18/34 total; 9/19 group 1 vs. 9/15 group 2; *p* = .51) and 16 patients showed cerebellar ataxia (16/34 total; 13/19 group 1 vs. 3/15 group 2; *p* = .007). Cerebellar ataxia was significantly more common in early recovered group.

As for atypical symptoms, there was no significant difference in the presence of other neurologic symptoms between the two groups (15/19, early recovered; 12/15, delayed recovered; *p* = 1). Additional symptoms included speech impairment, sensory abnormality, abnormal tongue movement, seizure, and fatigue.

The median and range of time to recovery after thiamine administration were as follows: 7 days (1-21) in group 1 and 40 days (28-90) in group 2.

MRI features

Table 2 summarizes the results of MRI features between groups 1 and 2.

All 34 patients underwent MRI. MRI was performed with contrast for 25 patients (14 patients in the early recovered [group 1] and 11 patients in the delayed recovered [group 2]).

T2-weighted image/fluid-attenuated inversion recovery

There was no significant difference between group 1 and group 2 in the presence of signal alteration in total sites nor in typical sites (in total sites 16/19 vs. 14/15, *p* = .61; in typical sites 16/19 vs. 13/15, *p* = 1). There was a significant difference between group 1 and group 2 (1/19 vs. 7/15, *p* = .01) in atypical sites. Table 3 shows the frequency of signal alterations on T2WI/FLAIR in each region.

**TABLE 2** Analysis of MR imaging features.

		Early recovered, N = 19 (14) ^a	Delayed recovered, N = 15 (11) ^a	p value
T2WI/FLAIR	Total sites	84%	93%	.61
	Typical sites	84%	87%	1
	Atypical sites	5.2%	47%	.01
Vasogenic edema	Total sites	21%	73%	.005
	Typical sites	21%	67%	.01
	Atypical sites	0%	20%	.08
Cytotoxic edema	Total sites	5.2%	40%	.03
	Typical sites	5.2%	33%	.07
	Atypical sites	0%	20%	.08
Postcontrast T1WI	Total sites	29%	36%	1
	Typical sites	21%	27%	1
	Atypical sites	7.1%	18%	.57

^aParentheses represent total number of WE patients with postcontrast T1WI. Total sites: either typical sites or atypical sites. Typical sites represent thalamus, periaqueductal area, periventricular region of the third ventricle, mamillary bodies, hypothalamus, and tectal plate. Atypical sites represent cerebellum, medulla, corpus callosum, pre- and postcentral gyri, basal ganglia, olive nuclei, and cranial nerve nuclei (VI, VII, VIII, XII). Abbreviations: FLAIR, fluid-attenuated inversion recovery; N, number of subjects; T1WI, T1-weighted image; T2WI, T2-weighted image.

Diffusion-weighted imaging

There were significant differences in the presence of both vasogenic edema and cytotoxic edema in total sites (vasogenic edema, 4/19 vs. 11/15, $p = .005$; cytotoxic edema, 1/19 vs. 6/15, $p = .03$). There was also a significant difference in the presence of vasogenic edema in typical sites (4/19 vs. 10/15, $p = .01$). Otherwise, there was no significant difference in the remaining analyzed MRI features. Details regarding vasogenic edema and cytotoxic edema are shown in Table 4.

Postcontrast T1WI

MRI with contrast was performed in 25 patients (14 in early recovery and 11 in delayed recovery). Among these patients, 8 patients showed contrast enhancement (4/14 in early recovery, 4/11 in delayed recovery). The anatomic structures that most frequently enhanced were the mamillary bodies (5 patients, 20%), followed by the medulla and olive nuclei (3 patients, 12%) and the tectal plate, hypothalamus, and CNN (1 patient each, 4%). The other sites had no contrast enhancement. There was no significant difference between group 1 and group 2 in any sites (in total sites 4/14 vs. 4/11, $p = 1$; in typical sites 3/14 vs. 3/11, $p = 1$; in atypical sites 1/14 vs. 2/11, $p = .57$). Table 5 summarizes the postcontrast evaluation.

Representative cases are shown in Figures 1-3.

DISCUSSION

Our study aimed to assess clinical and MRI features relating to the clinical outcome of WE by dividing WE into two groups: group 1 with recovery within 4 weeks following the diagnosis of WE and group 2 with unfavorable outcomes.

Our clinical data showed that age, sex, cause of thiamine deficiency, history of malignancy, and history of chemotherapy did not significantly associate with prognosis of WE. Regarding neurologic symptoms, cerebellar ataxia was significantly more often seen in the early recovered group than in the delayed recovered group (13/19 vs. 3/15). It is known that recovery from ataxia often occurs a few days after WE treatment.^{15,16} This result may be because our study constituted a heterogeneous population including varying basis of patients' underlying disease or because we were not able to reflect the severity of the symptoms in the analysis, resulting in more cases with milder symptoms included in the early recovered group and more cases with severe symptoms in the delayed recovery group. In previous studies, loss of equilibrium with incoordination of gait and trunk ataxia affected about 23% of WE patients.^{15,18} In our study, 16 patients showed cerebellar ataxia (16/34, 47%), twice the previously reported rate. The cause of this is unclear, possibly related to variation in underlying etiology of our patient population, as severity of alcohol abuse and other underrecognized clinical characteristics could potentially affect this discrepancy.

Regarding MRI features, there was no significant difference between the early recovered group and the delayed recovered group in the presence of high intensity in total sites and in typical sites on T2WI/FLAIR. However, the delayed recovered patients were more likely to show T2WI/FLAIR alterations in the atypical sites than the early recovered group. A previous study showed that consciousness level had a positive correlation with involvement of atypical areas (cerebral cortex, ninth CNN, corpus callosum, basal ganglia, and cerebellum).¹⁷ In addition to this correlation between clinical and imaging features, T2WI/FLAIR signal alteration in atypical areas could be potentially used as an imaging prognostic biomarker for the patient's assessment. The frequency of alteration in atypical sites has been reported as uncommon,⁷ but it is postulated that signal change in an atypical site could be a manifestation of greater severity of disease in WE.

Vasogenic edema and cytotoxic edema in typical or atypical sites were seen more frequently in the delayed recovered group than in the early recovered group. High intensity on DWI has been previously reported to reflect reversible vasogenic and/or cytotoxic edema, and can represent underlying vulnerability of patients to severe thiamine deficiency. Conventionally, T2WI and FLAIR are used for the diagnosis of WE, as variability regarding the presence of increased diffusion signal, and heterogeneity in associated ADC values, has resulted in a lack of clarity regarding the clinical utility of this sequence. As well as T2WI/FLAIR signal alteration in atypical areas, the presence of vasogenic and/or cytotoxic edema on DWI could potentially provide additional prognostic information, which can help clinicians to decide whether a patient with WE can recover from the

**TABLE 3** Frequency of signal alteration on T2WI/FLAIR.

Typical sites							
	Thal	Periaq	TV	TP	MB	Hypothal	
Total N = 34	67%	56%	44%	21%	24%	50%	
Early recovered N = 19	58%	47%	32%	5.2%	16%	37%	
Delayed recovered N = 15	80%	67%	60%	40%	33%	67%	
Atypical sites							
	Cer	Medu	CC	Pre- and post-CG	BG	ON	CNN (VI, VII, VIII, XII)
Total N = 34	2.9%	5.9%	2.9%	2.9%	8.8%	5.9%	21%
Early recovered N = 19	0%	0%	0%	0%	0%	0%	5.3%
Delayed recovered N = 15	6.7%	13%	6.7%	6.7%	20%	13%	40%

Abbreviations: BG, basal ganglia; CC, corpus callosum; Cer, Cerebellum; CNN, cranial nerve nuclei; FLAIR, fluid-attenuated inversion recovery; Hypothal, hypothalamus; MB, mamillary bodies; Medu, medulla; N, number of subjects; ON, olive nuclei; Periaq, periaqueductal gray matter; pre- and post-CG, pre- and postcentral gyri; T1WI, T1-weighted image; T2WI, T2-weighted image; Thal, medial thalami; TP, tectal plate; TV, periventricular region of the third ventricle.

TABLE 4 Frequency of signal alteration on diffusion-weighted imaging: Vasogenic edema or cytotoxic edema.

Typical sites							
	Thal	Periaq	TV	TP	MB	Hypothal	
Total N = 34	29% (8.8%)	24% (8.8%)	15% (2.9%)	5.9% (8.8%)	8.8% (15%)	18% (8.8%)	
Early recovered N = 19	16% (5.3%)	11% (5.3%)	0% (0)%%	0% (5.3%)	0% (0%)	5.3% (0%)	
Delayed recovered N = 15	47% (13%)	40% (13%)	33% (6.7%)	13% (13%)	20% (33%)	26% (20%)	
Atypical sites							
	Cer	Medu	CC	Pre- and post-CG	BG	ON	CNN (VI, VII, VIII, XII)
Total N = 34	2.9% (0%)	2.9% (2.9%)	2.9% (0%)	0% (2.9%)	5.9% (2.9%)	2.9% (2.9%)	5.9% (2.9%)
Early recovered N = 19	0% (0%)	0% (0%)	0% (0%)	0% (0%)	0% (0%)	0% (0%)	0% (0%)
Delayed recovered N = 15	6.7% (0%)	6.7% (6.7%)	6.7% (0%)	0% (6.7%)	13% (6.7%)	6.7% (6.7%)	13% (6.7%)

Note: The numbers represent the frequency of DWI signal alteration in each region. Parentheses represent frequency of cytotoxic edema.

Abbreviations: BG, basal ganglia; CC, corpus callosum; Cer, cerebellum; CNN, cranial nerve nuclei; DWI, diffusion-weighted imaging; Hypothal, hypothalamus; MB, mamillary bodies; Medu, medulla; N, number of subjects; ON, olive nuclei; Periaq, periaqueductal gray matter; pre- and post-CG, pre- and postcentral gyri; Thal, medial thalami; TP, tectal plate; TV, periventricular region of the third ventricle.

TABLE 5 Frequency of signal alteration on postcontrast T1WI.

Typical sites							
	Thal	Periaq	TV	TP	MB	Hypothal	
Total N = 25	0%	0%	0%	4%	20%	4%	
Early recovered N = 14	0%	0%	0%	0%	21%	0%	
Delayed recovered N = 11	0%	0%	0%	9.1%	18%	9.1%	
Atypical sites							
	Cer	Medu	CC	Pre- and post-CG	BG	ON	CNN (VI, VII, VIII, XII)
Total N = 25	0%	12%	0%	0%	0%	12%	4%
Early recovered N = 14	0%	7.1%	0%	0%	0%	7.1%	0%
Delayed recovered N = 11	0%	18%	0%	0%	0%	18%	9.1%

Note: The numbers represent the frequency of postcontrast T1WI signal alteration in each region.

Abbreviations: BG, basal ganglia; CC, corpus callosum; Cer, cerebellum; CNN, cranial nerve nuclei; Hypothal, hypothalamus; MB, mamillary bodies; Medu, medulla; N, number of subjects; ON, olive nuclei; Periaq, periaqueductal gray matter; pre- and post-CG, pre- and postcentral gyri; T1WI, T1-weighted image; Thal, medial thalami; TP, tectal plate; TV, periventricular region of the third ventricle.




FIGURE 1 A 44-year-old female with visual, gait, and speech impairment, with early recovery. She recovered back to normal baseline 2 weeks after starting thiamine infusion. (A, B) Fluid-attenuated inversion recovery sequences showed symmetric hyperintensity in the medial thalami and hypothalamus (arrows). (C, D) Diffusion-weighted imaging sequences did not reveal signal alteration.

symptom faster or not or to consider more intensive intervention such as early rehabilitation as well as standard thiamine infusion dose when patients are suspected to show delayed recovery from the symptoms.

In a previous study, contrast enhancement was present in 63% patients (26/41).¹⁹ In our study, contrast enhancement was observed in fewer patients (32%, 8/25) than previously stated and showed no significant difference in typical, atypical, or total sites between the two groups. However, enhancement of mamillary bodies was the only finding in two cases in our study, suggesting adding postcontrast T1WI sequence could be beneficial, as stated in the previous reports.¹⁹ Future studies with larger WE population evaluating the severity of sig-

nal alteration on each MRI sequences would provide more promising parameters to suggest WE prognosis.

Our study has several limitations. First, this is a retrospective design with a relatively small population for a longer period. Second, infusion of thiamine ranged from 500 to 1000 mg and MRI protocol were not equal throughout the 18-year period and between centers. Also, we included multiple scanners (1T to 3T). These factors could influence our results. Third, assessment of restricted diffusion was performed on the basis of visual assessment, as imaging examinations were obtained across multiple vendors with various parameters and magnetic field strengths. Finally, not all patients had postcontrast T1WI, resulting in a smaller available cohort in the evaluation of lesional enhancement.




FIGURE 2 A 28-year-old male presented with fatigue and showed delayed recovery. He recovered 3 months after starting thiamine infusion. (A, B) Fluid-attenuated inversion recovery sequences showed symmetric hyperintensity in the medial thalami, mamillary bodies, periaqueductal gray matter, and tectal plate (arrows). (C, D) Diffusion-weighted imaging sequences showed hyperintensity in the medial thalami and tectal plate, without (E) apparent diffusion coefficient alteration, suggesting vasogenic edema. (F) Postcontrast T1-weighted image showed no enhancement.




FIGURE 3 A 58-year-old male with altered mental status, nystagmus, ophthalmoparesis, swallowing dysfunction, and visual impairment. He showed delayed recovery. (A, B, C) Fluid-attenuated inversion recovery sequences showed symmetric hyperintensity in the medial thalami, mamillary bodies, periaqueductal gray matter, tectal plate, and medial vestibular nuclei (arrows). (D) Diffusion-weighted imaging sequences showed hyperintensity in the medial thalami with (E) apparent diffusion coefficient alteration suggesting cytotoxic edema (arrows). (F) Postcontrast T1-weighted image showed contrast enhancement in the tectal plate (arrow).

In conclusion, a lower incidence of T2WI/FLAIR abnormality in atypical sites and diffusion signal abnormality in total or typical sites with a lower incidence of cerebellar ataxia was observed in the early recovered group than in the group with unfavorable prognosis, suggesting that distribution of T2WI/FLAIR hyperintensities and careful analysis of the DWI sequence could be potentially used as a prognostic value in WE patients. Future studies with more patients are required to justify our study.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

ORCID

Yoshiaki Ota <https://orcid.org/0000-0001-8992-2156>



REFERENCES

1. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. *Lancet Neurol.* 2007;6:442–55.
2. Galvin R, Bråthen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. *Eur J Neurol.* 2010;17:1408–18.
3. Lough ME. Wernicke's encephalopathy: expanding the diagnostic toolbox. *Neuropsychol Rev.* 2012;22:181–94.
4. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. *Intern Med J.* 2014;44:911–5.
5. Chandrakumar A, Bhardwaj A, Jong GW. Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis. *J Basic Clin Physiol Pharmacol.* 2018;30:153–62.
6. Ogershok PR, Rahman A, Nestor S, et al. Wernicke encephalopathy in nonalcoholic patients. *Am J Med Sci.* 2002;323:107–11.
7. Ota Y, Capizzano AA, Moritani T, et al. Comprehensive review of Wernicke encephalopathy: pathophysiology, clinical symptoms and imaging findings. *Jpn J Radiol.* 2020;38:809–20.
8. Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. *J Neurol Neurosurg Psychiatry.* 1986;49:341–5.
9. Torvik A, Lindboe CF, Rodge S. Brain lesions in alcoholics: a neuropathological study with clinical correlations. *J Neurol Sci.* 1982;56:233–48.
10. Antunez E, Estruch R, Cardenal C, et al. Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. *AJR Am J Roentgenol.* 1998;171:1131–7.
11. Chung SP, Kim SW, Yoo IS, et al. Magnetic resonance imaging as a diagnostic adjunct to Wernicke's encephalopathy in the ED. *Am J Emerg Med.* 2003;21:497–502.
12. Manzo G, De Gennaro A, Cozzolino A, et al. MR imaging findings in alcoholic and nonalcoholic acute Wernicke's encephalopathy: a review. *Biomed Res Int.* 2014;2014:503596.
13. Zuccoli G, Pipitone N. Neuroimaging findings in acute Wernicke's encephalopathy: review of the literature. *AJR Am J Roentgenol.* 2009;192:501–8.
14. Jung YC, Chanraud S, Sullivan EV. Neuroimaging of Wernicke's encephalopathy and Korsakoff's syndrome. *Neuropsychol Rev.* 2012;22:170–80.
15. Victor M. The Wernicke-Korsakoff syndrome. In: Vinken PJ, Bruyn GW, editors. *Handbook of clinical neurology: volume 28, part II.* Amsterdam: North-Holland Publishing Company; 1976:243–70.
16. Sechi GP, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. *Lancet Neurol.* 2007;6:442–55.
17. Ha ND, Weon YC, Jang JC, et al. Spectrum of MR imaging findings in Wernicke encephalopathy: are atypical areas of involvement only present in nonalcoholic patients? *AJNR Am J Neuroradiol.* 2012;33:1398–402.
18. Ghez C. Vestibular paresis: a clinical feature of Wernicke's disease. *J Neurol Neurosurg Psychiatry.* 1969;32:134–9.
19. Zuccoli G, Santa Cruz D, Bertolini M, et al. MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. *AJNR Am J Neuroradiol.* 2009;30:171–6.

How to cite this article: Kitaguchi T, Ota Y, Liao E, et al. The role of MRI in the prognosis of Wernicke's encephalopathy. *J Neuroimaging.* 2023;33:917–925.

<https://doi.org/10.1111/jon.13143>